Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDP-118 Lotion vs Ultravate in Plaque Psoriasis
NCT02785172Phase 2Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Apr 2016
- Primary completion
- Dec 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of halobetasol propionate + tazarotene in plaque psoriasis (4 arms), sponsored by Valeant Pharmaceuticals. Primary endpoint: Percent of Subjects With Treatment Success at 2 weeks. Started Apr 2016; status: completed.
02
Drugs
halobetasol propionate + tazarotene
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02785172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02785172.